Position in AKTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$447,250
New position
Shares Held
25,000
first reported quarter
Ownership
0.045%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Ghisallo Capital Management LLC holds $16,940,228 across 16 Biotechnology names. AKTS ranks #11 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CAI |
Caris Life Sciences, Inc.
|
250,000 | $4,470,000 | |
| 2 | ALMS |
Alumis Inc.
|
100,000 | $2,203,000 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
100,000 | $1,920,000 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
5,000 | $1,610,950 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
25,000 | $1,452,750 | |
| 6 | CADL |
Candel Therapeutics, Inc.
|
200,000 | $980,000 | |
| 7 | DRUG |
Bright Minds Biosciences Inc.
|
11,000 | $802,670 | |
| 8 | EIKN |
Eikon Therapeutics, Inc.
|
70,000 | $740,600 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $447,250 | 25,000 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||